Product Reports Resources Pricing Login Book a demo

Temedica

Biotech & Life Sciences · Munich, Germany · Founded 2016

Health insights ecosystem for real-world evidence MoreLess

Temedica is a digital health company founded in 2016 in Munich, Germany, by Gloria Seibert and Benjamin Friedrich. Gloria Seibert, the CEO, was motivated to start the company due to her grandfather's battle with multiple sclerosis, which highlighted the need for more personalized patient support. Before Temedica, she worked as a business consultant at McKinsey and studied software engineering in Silicon Valley to gain the necessary technological expertise. Co-founder and Chief Medical Officer, PD Dr. med Benjamin Friedrich, brings extensive medical and academic experience from his work in radiology and neuroradiology at institutions like the Technical University of Munich.

The company operates a health insights ecosystem designed to centralize and analyze health data from various sources to generate real-world evidence. This ecosystem serves a wide range of clients, including pharmaceutical companies, research institutions, healthcare professionals, and patients. Temedica's business model is centered on partnerships with pharmaceutical firms, providing them with anonymized, GDPR-compliant data that offers insights into disease progression, patient journeys, and treatment effectiveness outside of traditional clinical trials. Partners have included major companies like Roche and AbbVie Germany.

Temedica's core offerings include digital patient companion apps and the Permea real-world insights platform. The companion apps are designed for patients with chronic conditions such as multiple sclerosis, psoriasis, and cancer, offering personalized guidance and support. The Permea platform integrates patient-generated data from these apps with other sources like registry and insurance data to provide a comprehensive view of patient care realities. This allows clients to receive customized analytics and reports that inform strategic decisions in areas like product development, market strategy, and patient engagement. The company has raised a total of $44.6 million in funding, including a Series B round that closed in November 2022.

Keywords: real-world evidence, health insights, digital health, patient journey, data analytics, personalized medicine, digital patient companion, pharma solutions, chronic disease management, healthcare data, real-world data, Permea, health-tech, patient-generated data, omnichannel engagement, disease progression, treatment effectiveness, medication adherence, clinical research, patient-centric care

Company overview

Temedica company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2016
Headquarters
Munich, Germany
Employees
67
Open positions
3
Dealroom signal
70.6
client focusb2btechnologyArtificial IntelligencetechnologyDeep TechtechnologyMachine LearningtechnologyNatural Language Processingsub industryBioTechnologysub industryHealth Platformbusiness modelSaaSindustryHealthsectorBiotechnologysectorClinicalsectorRemote MonitoringsectorCore AIsectorDigital Therapeutics

Valuation & funding

Temedica funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BEquity / VC Nov 2022 $28M $110M MIG Capital
SERIES AEquity / VC Jan 2020 $19M $75M G+J Ventures · MIG Capital · Bernd Wendeln · Santo Venture Capital
Showing 2 recorded eventsUnlock the complete deal history →

Financials

Revenue, earnings and profit over time

Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.

YearRevenueGrowthProfitMargin
2026 $3.3M 0% −$10M -313.6%
2025 $3.3M 0% −$10M -313.6%
2024 $3.3M 0% −$10M -313.6%
2023 $3.3M 0%
2022 $3.3M 0%
2021 $3.3M +200%
2020 $1.1M
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Temedica website traffic

Latest recorded traffic for Temedica is 5.4K monthly website visits, down 19.4% over the last three months. Temedica's team declined 6.9% over the past year.

Latest monthly visits5.4K 3-month web change-19.4% 1-year team growth-6.9%
Monthly website visits116 observations · Dec 2016–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Temedica compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Temedica's talent

Book a demo to see the people
Team profiled 19 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

6 investors on Temedica's cap table

Sourced from Dealroom's funding and investor records.

Series A 4 investors entered at this stage
G+J Ventures
MIG Capital
Bernd Wendeln
Santo Venture Capital
Other known 2 additional known investors
Christophe Aumaître
WENVEST Capital

Global footprint

Where Temedica has talent and traffic

Workforce by country
6 countries with
team presence
🇩🇪 Germany90%
🇮🇳 India1.7%
🇮🇹 Italy1.7%
🇦🇹 Austria1.7%
🇵🇰 Pakistan1.7%
Top 5 of 6 shown

In the news

Latest news about Temedica

Recent press, funding announcements, and product moves mentioning Temedica — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Temedica

An AI-synthesized read of the highest-engagement posts about Temedica on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Temedica’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.